HCPCS Level II code G0219 denotes whole-body PET imaging performed specifically for melanoma in situations identified as non-covered indications. This code matters nationally because PET imaging plays a central role in staging and surveillance of melanoma, and designation of non-covered use influences billing, appeals, and utilization management across payers. Key payers considered include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

Readers will find a concise explanation of the code’s clinical intent and common sites of service, an overview of how major payers treat non-covered PET imaging for melanoma, and contextual information on coding and billing implications. The publication highlights benchmarks and policy-related considerations relevant to coverage determination, common modifier usage patterns (where available), and operational impacts for imaging centers and hospital outpatient departments. It also outlines typical clinical scenarios that prompt use of whole-body PET for melanoma and notes where input data was not provided. This resource is intended for revenue cycle professionals, medical coders, and policy analysts seeking a national-level briefing on billing and coverage considerations tied to G0219.